Chloramphenicol induced bone marrow suppression

Adel A Yunis

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

This review is limited to a discussion on the pathogenesis of chloramphenicol (CAP) toxicity. Classification of hematologic toxicity from CAP into two types with distinct clinical features was suggested from a detailed analysis of a large number of cases of incidental CAP toxicity collected from the literature. Current evidence has reinforced the validity of this classification and supports the concept of a lack of relationship between reversible erythroid suppression and aplastic anemia from CAP. Ample data are available to indicate that reversible bone marrow suppression from CAP is a pharmacologic effect and results from inhibition of mitochondrial protein synthesis and consequent mitochondrial injury. Although some evidence has been provided to suggest that bone marrow aplasia occurs on the basis of a genetically determined biochemical predisposition involving the pathway of DNA synthesis, this concept cannot be considered conclusive at present. The difference in the inhibitory capacity of CAP and thiamphenicol (TAP) on DNA synthesis is of considerable interest, but its significance awaits definitive clinical data on TAP and more experimental work on the various CAP analogues. Whether the impression that TAP does not cause bone marrow aplasia will be confirmed from clinical studies now in progress remains to be seen.

Original languageEnglish (US)
Pages (from-to)225-234
Number of pages10
JournalSeminars in Hematology
Volume10
Issue number3
StatePublished - 1973

Fingerprint

Chloramphenicol
Bone Marrow
Thiamphenicol
Aplastic Anemia
Mitochondrial Proteins
DNA
Wounds and Injuries

ASJC Scopus subject areas

  • Hematology

Cite this

Chloramphenicol induced bone marrow suppression. / Yunis, Adel A.

In: Seminars in Hematology, Vol. 10, No. 3, 1973, p. 225-234.

Research output: Contribution to journalArticle

Yunis, AA 1973, 'Chloramphenicol induced bone marrow suppression', Seminars in Hematology, vol. 10, no. 3, pp. 225-234.
Yunis, Adel A. / Chloramphenicol induced bone marrow suppression. In: Seminars in Hematology. 1973 ; Vol. 10, No. 3. pp. 225-234.
@article{3dadc5a1c6ec47a4b5dab3e3a11e6f0f,
title = "Chloramphenicol induced bone marrow suppression",
abstract = "This review is limited to a discussion on the pathogenesis of chloramphenicol (CAP) toxicity. Classification of hematologic toxicity from CAP into two types with distinct clinical features was suggested from a detailed analysis of a large number of cases of incidental CAP toxicity collected from the literature. Current evidence has reinforced the validity of this classification and supports the concept of a lack of relationship between reversible erythroid suppression and aplastic anemia from CAP. Ample data are available to indicate that reversible bone marrow suppression from CAP is a pharmacologic effect and results from inhibition of mitochondrial protein synthesis and consequent mitochondrial injury. Although some evidence has been provided to suggest that bone marrow aplasia occurs on the basis of a genetically determined biochemical predisposition involving the pathway of DNA synthesis, this concept cannot be considered conclusive at present. The difference in the inhibitory capacity of CAP and thiamphenicol (TAP) on DNA synthesis is of considerable interest, but its significance awaits definitive clinical data on TAP and more experimental work on the various CAP analogues. Whether the impression that TAP does not cause bone marrow aplasia will be confirmed from clinical studies now in progress remains to be seen.",
author = "Yunis, {Adel A}",
year = "1973",
language = "English (US)",
volume = "10",
pages = "225--234",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Chloramphenicol induced bone marrow suppression

AU - Yunis, Adel A

PY - 1973

Y1 - 1973

N2 - This review is limited to a discussion on the pathogenesis of chloramphenicol (CAP) toxicity. Classification of hematologic toxicity from CAP into two types with distinct clinical features was suggested from a detailed analysis of a large number of cases of incidental CAP toxicity collected from the literature. Current evidence has reinforced the validity of this classification and supports the concept of a lack of relationship between reversible erythroid suppression and aplastic anemia from CAP. Ample data are available to indicate that reversible bone marrow suppression from CAP is a pharmacologic effect and results from inhibition of mitochondrial protein synthesis and consequent mitochondrial injury. Although some evidence has been provided to suggest that bone marrow aplasia occurs on the basis of a genetically determined biochemical predisposition involving the pathway of DNA synthesis, this concept cannot be considered conclusive at present. The difference in the inhibitory capacity of CAP and thiamphenicol (TAP) on DNA synthesis is of considerable interest, but its significance awaits definitive clinical data on TAP and more experimental work on the various CAP analogues. Whether the impression that TAP does not cause bone marrow aplasia will be confirmed from clinical studies now in progress remains to be seen.

AB - This review is limited to a discussion on the pathogenesis of chloramphenicol (CAP) toxicity. Classification of hematologic toxicity from CAP into two types with distinct clinical features was suggested from a detailed analysis of a large number of cases of incidental CAP toxicity collected from the literature. Current evidence has reinforced the validity of this classification and supports the concept of a lack of relationship between reversible erythroid suppression and aplastic anemia from CAP. Ample data are available to indicate that reversible bone marrow suppression from CAP is a pharmacologic effect and results from inhibition of mitochondrial protein synthesis and consequent mitochondrial injury. Although some evidence has been provided to suggest that bone marrow aplasia occurs on the basis of a genetically determined biochemical predisposition involving the pathway of DNA synthesis, this concept cannot be considered conclusive at present. The difference in the inhibitory capacity of CAP and thiamphenicol (TAP) on DNA synthesis is of considerable interest, but its significance awaits definitive clinical data on TAP and more experimental work on the various CAP analogues. Whether the impression that TAP does not cause bone marrow aplasia will be confirmed from clinical studies now in progress remains to be seen.

UR - http://www.scopus.com/inward/record.url?scp=0015860447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015860447&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 225

EP - 234

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3

ER -